OK
The Universal Selection Source:
Adhesives Ingredients
Industry News

Kollodis BioSciences, Inc. Enters Into Japanese Distribution Agreement With Funakoshi Co., Ltd.

Published on 2009-10-28. Author : SpecialChem

MALDEN, MA -- Kollodis BioSciences, Inc. announced that it has entered into a Distribution Agreement with Funakoshi Co., Ltd. for the distribution of Kollodis BioSciences, Inc.'s MAPTrix® ECM line of products for cell culture and related applications. The non-exclusive agreement provides Funakoshi with the rights to distribute Kollodis' cell culture products in Japan.

Dr. Louis M. Scarmoutzos, President & CEO of Kollodis BioSciences, Inc., stated, "We are absolutely delighted with this distribution agreement. Funakoshi is a well-established and highly reputable partner for bringing Kollodis' research products to the Japanese market. They have an excellent reputation with their customers and suppliers. We look forward to a lasting and fruitful relationship with Funakoshi."

Among the Mussel Adhesive Protein based matrix (MAPTrix®) ECM line of products are reagents with genetically incorporated bioactive peptides (recognition peptides) that mimic the extracellular matrix (ECM) activity of collagen, fibronectin, laminin, and vitronectin proteins. The bioactive peptide mimics the extracellular matrix (ECM) protein and provides for cell attachment, spreading and growth. The mussel adhesive protein confers biocompatible adhesion to a wide variety of surfaces.

About Funakoshi Co., Ltd.

Funakoshi Co., Ltd. is a leading Japanese distributor of biotech reagents and instrumentation for researchers in the life sciences and related fields. Funakoshi offers leading edge products and technologies for Japanese researchers from all over the world.

Kollodis BioSciences, Inc.

Kollodis BioSciences, Inc. has successfully developed a proprietary recombinant protein expression system for the large scale production of various mussel adhesive proteins (MAP). Kollodis is developing MAP-based smart biomaterials for biotech, medical and industrial applications. The Company's proprietary and patented MAPTrix® platform technology recombinantly incorporates bioactive peptides into a mussel adhesive protein (MAP) for cell culture and related applications.

Source: Kollodis BioSciences


FEICA 2018 European Adhesive and Sealant Conference and EXPO
Channel Alerts

Receive weekly digests on hot topics

Back to Top